• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

埃德蒙顿症状评估系统在筛查焦虑和抑郁中的效用。

The utility of the Edmonton Symptom Assessment System in screening for anxiety and depression.

机构信息

Department of Psychosocial Oncology and Palliative Care, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada.

出版信息

Eur J Cancer Care (Engl). 2013 Jan;22(1):60-9. doi: 10.1111/j.1365-2354.2012.01369.x. Epub 2012 Jun 14.

DOI:10.1111/j.1365-2354.2012.01369.x
PMID:22694595
Abstract

The Edmonton Symptom Assessment System (ESAS) is a common screening tool in cancer, although its validity for distress screening is unproven. Here, screening performance of the ESAS anxiety (ESAS-A) and depression (ESAS-D) items were validated against the anxiety [Generalised Anxiety Disorder-7 (GAD-7)] and depression [Patient Health Questionnaire-9 (PHQ-9)] subscales of the PHQ. A total of 1215 cancer patients completed the Distress Assessment and Response Tool (DART), a computerised distress screening instrument. Spearman's rank correlation coefficients and receiver operating characteristic curve analyses were used to evaluate the ability of ESAS-A and ESAS-D to identify moderate distress (GAD-7/PHQ-9 ≥ 10). Spearman's rank correlation coefficients comparing ESAS-A and ESAS-D with GAD-7 and PHQ-9 were 0.74 and 0.72 respectively. Areas under the receiver operating characteristic curves were 0.89 and 0.88 for anxiety and depression respectively. A cut-off of ≥3 on ESAS-A demonstrated a sensitivity of 0.91, specificity of 0.68, positive predictive value of 0.34 and negative predictive value of 0.97. A cut-off of ≥2 on the ESAS-D demonstrated a sensitivity of 0.86, specificity of 0.72, positive predictive value of 0.46 and negative predictive value of 0.95. High sensitivities of ESAS-A and ESAS-D at certain cut-offs suggest they have use in ruling-out distress. However, their low specificities indicate secondary screening is needed to rule-in anxiety or depression for case-finding.

摘要

埃德蒙顿症状评估系统(ESAS)是癌症中常用的筛查工具,但其用于筛查苦恼的有效性尚未得到证实。在这里,ESAS 焦虑(ESAS-A)和抑郁(ESAS-D)项目的筛查性能通过 PHQ 的焦虑[广泛性焦虑障碍-7(GAD-7)]和抑郁[患者健康问卷-9(PHQ-9)]子量表进行了验证。共有 1215 名癌症患者完成了计算机化的痛苦筛查工具 DART(痛苦评估和反应工具)。使用 Spearman 等级相关系数和受试者工作特征曲线分析来评估 ESAS-A 和 ESAS-D 识别中度痛苦(GAD-7/PHQ-9≥10)的能力。ESAS-A 和 ESAS-D 与 GAD-7 和 PHQ-9 的 Spearman 等级相关系数分别为 0.74 和 0.72。焦虑和抑郁的受试者工作特征曲线下面积分别为 0.89 和 0.88。ESAS-A 的≥3 切点显示出 0.91 的敏感性、0.68 的特异性、0.34 的阳性预测值和 0.97 的阴性预测值。ESAS-D 的≥2 切点显示出 0.86 的敏感性、0.72 的特异性、0.46 的阳性预测值和 0.95 的阴性预测值。ESAS-A 和 ESAS-D 在某些切点的高敏感性表明它们在排除痛苦方面具有一定的作用。然而,它们的低特异性表明需要进行二级筛查以确认焦虑或抑郁的存在,以便进行病例发现。

相似文献

1
The utility of the Edmonton Symptom Assessment System in screening for anxiety and depression.埃德蒙顿症状评估系统在筛查焦虑和抑郁中的效用。
Eur J Cancer Care (Engl). 2013 Jan;22(1):60-9. doi: 10.1111/j.1365-2354.2012.01369.x. Epub 2012 Jun 14.
2
Frequency of anxiety and depression and screening performance of the Edmonton Symptom Assessment Scale in a psycho-oncology clinic.焦虑和抑郁的频率以及心理肿瘤学诊所中 Edmonton 症状评估量表的筛查性能。
Psychooncology. 2022 Feb;31(2):290-297. doi: 10.1002/pon.5813. Epub 2021 Sep 22.
3
Sensitivity and specificity of the Distress Thermometer and a two-item depression screen (Patient Health Questionnaire-2) with a 'help' question for psychological distress and psychiatric morbidity in patients with advanced cancer.对于晚期癌症患者,使用“求助”问题的心理困扰 Distress Thermometer 与两项抑郁筛查工具(患者健康问卷-2)在评估心理困扰和精神疾病发病率方面的敏感性和特异性。
Psychooncology. 2012 Dec;21(12):1275-84. doi: 10.1002/pon.2042. Epub 2011 Sep 15.
4
The Edmonton Symptom Assessment System as a screening tool for depression and anxiety.作为抑郁症和焦虑症筛查工具的埃德蒙顿症状评估系统。
J Palliat Med. 2006 Apr;9(2):296-303. doi: 10.1089/jpm.2006.9.296.
5
Screening for anxiety and depression in dialysis patients: comparison of the Hospital Anxiety and Depression Scale and the Beck Depression Inventory.透析患者焦虑和抑郁的筛查:医院焦虑和抑郁量表与贝克抑郁量表的比较。
J Psychosom Res. 2012 Aug;73(2):139-44. doi: 10.1016/j.jpsychores.2012.04.015. Epub 2012 Jun 11.
6
Frequency of reporting and predictive factors for anxiety and depression in patients with advanced cancer.晚期癌症患者焦虑和抑郁的报告频率及预测因素。
Clin Oncol (R Coll Radiol). 2012 Mar;24(2):139-48. doi: 10.1016/j.clon.2011.05.003. Epub 2011 Jun 8.
7
Evaluation of screening instruments for depression and anxiety in breast cancer survivors.乳腺癌幸存者中抑郁和焦虑的筛查工具评估。
Breast Cancer Res Treat. 2010 Jul;122(2):573-8. doi: 10.1007/s10549-009-0669-6. Epub 2009 Dec 4.
8
Screening for psychological distress in neurosurgical brain tumor patients using the Patient Health Questionnaire-2.用患者健康问卷-2 对神经外科脑肿瘤患者进行心理困扰筛查。
Psychooncology. 2013 Aug;22(8):1895-900. doi: 10.1002/pon.3237. Epub 2012 Dec 12.
9
Screening for symptoms of anxiety and depression in patients treated with renal replacement therapy: utility of the Edmonton Symptom Assessment System-Revised.在接受肾脏替代治疗的患者中筛查焦虑和抑郁症状:埃德蒙顿症状评估系统修订版的效用。
Qual Life Res. 2022 Feb;31(2):597-605. doi: 10.1007/s11136-021-02910-5. Epub 2021 Jun 17.
10
Validity of the Hospital Anxiety and Depression Scale and Patient Health Questionnaire-9 to screen for depression in patients with coronary artery disease.医院焦虑抑郁量表及患者健康问卷-9用于筛查冠心病患者抑郁状态的效度
Gen Hosp Psychiatry. 2007 Sep-Oct;29(5):417-24. doi: 10.1016/j.genhosppsych.2007.06.005.

引用本文的文献

1
Emergency palliative cancer care: anxiety and midazolam.癌症紧急姑息治疗:焦虑与咪达唑仑
BMC Palliat Care. 2025 Mar 13;24(1):64. doi: 10.1186/s12904-025-01687-5.
2
Self-reported MeasUrement of Physical and PsychosOcial Symptoms Response Tool (SUPPORT-dialysis): systematic symptom assessment and management in patients on in-centre haemodialysis - a parallel arm, non-randomised feasibility pilot study protocol.自我报告的身体和心理社会症状反应工具测量(SUPPORT-dialysis):中心血液透析患者的系统症状评估和管理 - 一项平行臂、非随机可行性试点研究方案。
BMJ Open. 2024 Jan 30;14(1):e080712. doi: 10.1136/bmjopen-2023-080712.
3
Patient-reported mental health and well-being trajectories in oncology patients during radiation therapy: an exploratory retrospective cohort analysis using the Ontario Cancer Registry.
放射治疗期间肿瘤患者自我报告的心理健康和幸福轨迹:一项使用安大略癌症登记处的探索性回顾性队列分析
Qual Life Res. 2023 Oct;32(10):2899-2909. doi: 10.1007/s11136-023-03430-0. Epub 2023 May 4.
4
Screening for Distress and Health Outcomes in Head and Neck Cancer.筛查头颈部癌症患者的痛苦和健康结局。
Curr Oncol. 2022 May 24;29(6):3793-3806. doi: 10.3390/curroncol29060304.
5
The impact of symptom screening on survival among patients with cancer across varying levels of pre-diagnosis psychiatric care.症状筛查对不同水平预诊断精神卫生保健的癌症患者生存的影响。
Cancer Med. 2022 Feb;11(3):838-846. doi: 10.1002/cam4.4479. Epub 2021 Dec 20.
6
Adapting the collaborative care model to palliative care: Establishing mental health-serious illness care integration.将协作护理模式应用于姑息治疗:建立心理健康与重症疾病护理的整合。
Palliat Support Care. 2021 Dec;19(6):642-645. doi: 10.1017/S147895152100170X.
7
Frequency of anxiety and depression and screening performance of the Edmonton Symptom Assessment Scale in a psycho-oncology clinic.焦虑和抑郁的频率以及心理肿瘤学诊所中 Edmonton 症状评估量表的筛查性能。
Psychooncology. 2022 Feb;31(2):290-297. doi: 10.1002/pon.5813. Epub 2021 Sep 22.
8
Longitudinal health utilities, symptoms and toxicities in patients with rearranged lung cancer treated with tyrosine kinase inhibitors: a prospective real-world assessment.接受酪氨酸激酶抑制剂治疗的肺癌患者的纵向健康效用、症状和毒性:一项前瞻性真实世界评估。
Curr Oncol. 2020 Dec;27(6):e552-e559. doi: 10.3747/co.27.6563. Epub 2020 Dec 1.
9
Randomized control trial of advanced cancer patients at a private hospital in Kenya and the impact of dignity therapy on quality of life.肯尼亚一家私立医院晚期癌症患者的随机对照试验及尊严疗法对生活质量的影响。
BMC Palliat Care. 2020 Jul 23;19(1):114. doi: 10.1186/s12904-020-00614-0.
10
Personalized symptom management: a quality improvement collaborative for implementation of patient reported outcomes (PROs) in 'real-world' oncology multisite practices.个性化症状管理:一项在“真实世界”肿瘤多中心实践中实施患者报告结局(PROs)的质量改进协作项目。
J Patient Rep Outcomes. 2020 Jun 17;4(1):47. doi: 10.1186/s41687-020-00212-x.